These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 29512196

  • 21. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F.
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [Abstract] [Full Text] [Related]

  • 22. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A.
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 24. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M.
    J Eur Acad Dermatol Venereol; 2020 Aug 01; 34(8):1744-1749. PubMed ID: 32289190
    [Abstract] [Full Text] [Related]

  • 25. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.
    J Dermatol; 2018 Sep 01; 45(9):1053-1062. PubMed ID: 29905383
    [Abstract] [Full Text] [Related]

  • 26. Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.
    Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J, Han C, Kirby B.
    Acta Derm Venereol; 2024 Sep 05; 104():adv41053. PubMed ID: 39233617
    [Abstract] [Full Text] [Related]

  • 27. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 Sep 05; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 28. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
    Li N, Teeple A, Muser E, You Y, Song M, Armstrong AW.
    J Dermatolog Treat; 2022 Feb 05; 33(1):278-283. PubMed ID: 32233940
    [Abstract] [Full Text] [Related]

  • 29. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A, Muser E.
    J Med Econ; 2019 Dec 05; 22(12):1268-1273. PubMed ID: 31199173
    [Abstract] [Full Text] [Related]

  • 30. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Dec 05; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 31. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
    Mease PJ, Genovese MC, Mutebi A, Viswanathan HN, Chau D, Feng J, Erondu N, Nirula A.
    J Rheumatol; 2016 Feb 05; 43(2):343-9. PubMed ID: 26773108
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L.
    Br J Dermatol; 2018 Jan 05; 178(1):114-123. PubMed ID: 28635018
    [Abstract] [Full Text] [Related]

  • 33. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
    Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L.
    J Am Acad Dermatol; 2022 Apr 05; 86(4):827-834. PubMed ID: 34798201
    [Abstract] [Full Text] [Related]

  • 34. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG, Merola JF, Rowland K, Miller M, Yang YW, Yu J, You Y, Chan D, Thaçi D, Langley RG.
    Br J Dermatol; 2023 Jul 07; 189(1):42-52. PubMed ID: 37022762
    [Abstract] [Full Text] [Related]

  • 35. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.
    J Am Acad Dermatol; 2018 Jan 07; 78(1):90-99.e1. PubMed ID: 28993005
    [Abstract] [Full Text] [Related]

  • 36. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W, Egeberg A, Sonkoly E, Gorecki P, Tjärnlund A, Buyze J, Wegner S, McGonagle D.
    Arthritis Res Ther; 2023 Sep 15; 25(1):169. PubMed ID: 37715294
    [Abstract] [Full Text] [Related]

  • 37. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug 15; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 38. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr 15; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 39. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 15; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug 15; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.